
QNCX P/E Ratio
P/E Ratio as of Jun 13, 2025: -1.02
Average-0.7880
Median-0.7700
Minimum-1.02
Maximum-0.6100
-1.02
Past Month-0.42 (70.00%)
The P/E ratio for QNCX is -1.02 as of Jun 13, 2025. This represents a increase of 5.15% compared to its 12-month average P/E ratio of -0.97. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Quince Therapeutics Inc P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Quince Therapeutics Inc’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Quince Therapeutics Inc to industry peers.
Quince Therapeutics Inc P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Quince Therapeutics Inc’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Quince Therapeutics Inc to industry peers.
QNCX P/E Ratio Insights
See Quince Therapeutics Inc’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in QNCX
Order type
Buy in
Order amount
Est. shares
0 shares
QNCX P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $1.06 | -0.76 |
May 1, 2025 | $1.08 | -0.82 |
Apr 1, 2025 | $1.27 | -0.97 |
Mar 3, 2025 | $1.45 | -1.16 |
Feb 3, 2025 | $1.60 | -1.28 |
Jan 2, 2025 | $1.88 | -1.51 |
QNCX End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -1.02 | -32.00% |
2024 | -1.50 | +11.11% |
2023 | -1.35 | +365.52% |
2022 | -0.29 | -93.05% |
2021 | -4.17 | -60.51% |
2020 | -10.56 | — |
FAQs About Quince Therapeutics Inc (QNCX) P/E ratio
The latest P/E ratio of QNCX is -1.02, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Quince Therapeutics Inc’s last 12-month average P/E ratio is -0.97, compared to its current P/E ratio of -1.02. This reflects a increase of 5.15%.
Quince Therapeutics Inc’s current P/E ratio of -1.02 is higher than its last 12-month average P/E of -0.97. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Quince Therapeutics Inc’s average P/E ratio over the last 3 years is -1.04. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Quince Therapeutics Inc’s average P/E ratio over the last 5 years is -6.15. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.